Ardsley Advisory Partners LP Pacira Bio Sciences, Inc. Transaction History

Ardsley Advisory Partners LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$25.5 - $31.51 $2.21 Million - $2.73 Million	86,600 Added 17.55%	580,000 $16.6 Million
Q1 2024 May 15, 2024	BUY	$27.7 - $35.48 $5.3 Million - $6.79 Million	191,400 Added 63.38%	493,400 $14.4 Million
Q4 2023 Feb 14, 2024	SELL	$26.32 - $34.31 $210,560 - $274,480	-8,000 Reduced 2.58%	302,000 $10.2 Million
Q3 2023 Nov 14, 2023	BUY	$30.68 - $40.09 $9.51 Million - $12.4 Million	310,000 New	310,000 $9.51 Million
Q3 2022 Nov 14, 2022	BUY	$51.24 - $58.89 $1.79 Million - $2.06 Million	35,000 Added 25.93%	170,000 $9.04 Million
Q2 2022 Aug 15, 2022	BUY	$51.49 - $81.64 $1.8 Million - $2.86 Million	35,000 Added 35.0%	135,000 $7.87 Million
Q1 2022 May 16, 2022	BUY	$60.03 - $76.49 $6 Million - $7.65 Million	100,000 New	100,000 $7.63 Million

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $868M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Ardsley Advisory Partners LP, based on Form 13F filings with the SEC.

Stay updated on Ardsley Advisory Partners LP with notifications on news.